ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Pregabalin (Lyrica) may support meaningful improvement in Fibromyalgia sleep maintenance
Sunday 13 May 2012
By Thomas Roth, PhD, et al.
[Ed Note: Wake after sleep onset (WASO) was measured. This “quantifies the night time minutes spent awake after falling into a persistent sleep state, and is considered one of the key sleep parameters for characterizing the effect of a hypnotic [sleep-inducing] drug.” In this study the average reduction in minutes of wake after sleep onset for FM patients taking a daily pregabalin dose of 300mg to 450mg was 19.2 minutes. Additionally, average total sleep time was 25.5 minutes greater for the pregabalen group – 6.6 hours vs 6.2 for placebo group. See a MedPage Today physician CME summary for details on other measures not mentioned in the abstract (http://www.medpagetoday.com/clinical-context/Fibromyalgia/31924.)
Lead investigator Thomas Roth, PhD, directs the Henry Ford Health System Sleep Disorders and Research Center, Detroit.]
To assess the effect of pregabalin on polysomnographic (PSG) measures of sleep and patient-rated sleep, tiredness, and pain in fibromyalgia patients.
We performed a randomized, double-blind, placebo-controlled, 2-period crossover PSG study.
Patients ages 18 years or older with fibromyalgia satisfied subjective and objective sleep disturbance criteria prior to randomization.
• Eligible patients were randomized (1:1) to pregabalin (300-450 mg/day) or placebo for crossover period 1, and vice versa for period 2.
• Each crossover period comprised a dose-adjustment and dose-maintenance phase, with a 2-week taper/washout between periods.
• In-laboratory PSGs were recorded during 2 consecutive nights at screening and at the end of each crossover period.
The primary end point was the difference in sleep maintenance defined by PSG-recorded wake after sleep onset (WASO; minutes) between 4 weeks of treatment with pregabalin and with placebo.
Other PSG measures; patient-rated sleep, tiredness, and pain; and tolerability were assessed.
Of 119 patients randomized (103 women [86.6%], mean age 48.4 years), 102 (85.7%) completed both periods.
• Patients treated with pregabalin showed a reduction in PSG-determined WASO versus treatment with placebo (week 4 difference: -19.2 minutes [95% confidence interval (95% CI) -26.7, -11.6]; P < 0.0001).
• Pain score improved (decreased) with pregabalin versus placebo treatment at all 4 weeks (week 4 difference: -0.52 [95% CI -0.90, -0.14]; P = 0.0084).
Modest (p = <0.3) but significant correlations were found between PSG sleep assessments and ratings of pain and sleep quality. [Note: the p score of <0.3 would indicate the chances of this result occurring by chance would be less than 3 in 10.]
Frequently reported all-causality adverse events (pregabalin versus placebo) were:
• Dizziness (30.4% versus 9.9%),
• Somnolence (20.5% versus 4.5%),
• And headache (8.9% versus 8.1%).
• Patients with fibromyalgia treated with pregabalin had statistically significant and meaningful improvements in sleep, as assessed by PSG.
• Patients with fibromyalgia also reported decreased daily pain.
• Pregabalin was well tolerated.
ClinicalTrials.gov identifier: NCT00883740.
Arthritis Care & Research, April 2012;64:597-606. PMID: 22232085, by Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. Sleep Disorders and Research Center, Henry Ford Health System, Detroit, Michigan; Sleep Disorders Center of Georgia, Atlanta; Pfizer Inc., New York, NY, USA. [Email: email@example.com] Research funded by Pfizer Inc. For details on investigators’ research funding and stock ownership/options, see http://onlinelibrary.wiley.com/doi/10.1002/acr.21595/full.
The above originally appeared here.
blog comments powered by Disqus